ArticleMedical science monitor : international medical journal of experimental and clinical research2025
Quality of Life Among Polish Patients with Multiple Myeloma: A Cross-Sectional Study.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND The quality of life of patients with multiple myeloma is an important parameter in the assessment of patient condition. The aim of this study was to determine the quality of life among Polish patients with multiple myeloma. MATERIAL AND METHODS The study was conducted in 4 Polish centers from August 2020 to December 2021 using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in paper and electronic versions. The patients were divided into groups based on their treatment method (chemotherapy, autologous hematopoietic stem cell transplantation [autoHSCT], or supportive therapy), age, and sex. RESULTS Responses were obtained from the patients during chemotherapy (n=98), after autoHSCT (n=87), and during supportive therapy following completion of treatment to maintain disease remission (n=61). For the entire study population, the highest scores were recorded for social functioning (M=65.718, SD=23.886) and emotional functioning (M=60.467, SD=22.353). Fatigue was the most burdensome symptom reported by patients (M=59.937, SD=22.546). Older patients reported lower quality of life and more severe disease-related symptoms. Patient sex did not have a statistically significant effect on most of the analyzed parameters. Patients receiving supportive therapy had the highest level of quality of life (P<0.001) and the lowest severity of most symptoms (P<0.001). CONCLUSIONS In this study, the quality of life of patients with multiple myeloma was found to be linked to treatment method and patient age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.